Alessandra GraziottinAlessandra Graziottin
Condividi su
28/02/2011

Female sexual dysfunctions: future of medical therapy


Graziottin A. Gambini D. Perelman M.A.
Female sexual dysfunctions: future of medical therapy
in: Abdel-Hamid I.A. (Ed), Advances in sexual medicine: drug discovery issues, Research Signpost, Kerala, India, 2009, p. 403-432

Female sexual dysfunction (FSD) is age related, progressive and highly prevalent, affecting up to 20% to 43% of women in the fertile age, and 48% of the older postmenopausal women. Pelvic floor disorders are among the most important and yet neglected medical contributors to womens' sexual dysfunctions.
This chapter will briefly review the pathophysiology of women's sexual function and dysfunction, and focus on clinical use of hormonal (hormone therapy (HT), tibolone, testosterone patches) and non-hormonal agents including those impacting the central nervous system (CNS), such as bupropion, flibanserin, and bremelanotide, in the treatment of FSD. New perspectives on genital treatments: hormonal (vaginal estrogens, vulvar testosterone) and non hormonal (vasoactive drugs, botulin toxin) will be briefly considered.

top


Available documents:
Full text of the chapter


By courtesy of Research Signpost

FAIR USE: The content of this paper can be downloaded, printed and read for strictly personal and non-profit use. Any citation for didactic and/or scientific purpose must quote the title of the document, the name of the author(s), the data of the book or journal, and the URL of the site (www.alessandragraziottin.it).

WARNING: Every therapy must be discussed, tailored, prescribed and monitored by the M.D. personally consulted. Every information presented in this website can not surrogate the personal relationship with the caring physician nor be utilized without specific medical advice.